Overview of Флавамед

Understanding Flavamed: Identity and Core Function

Property	Description
Active Ingredient	Ambroxol Hydrochloride
Form	Oral Solution, Tablets, Syrups
Pharmacological Class	Mucolytic Agent / Expectorant
Common Use	Symptomatic relief of productive cough
Origin	Synthetic derivative

Flavamed is an Over-the-Counter (OTC) medicine manufactured by Berlin-Chemie AG (Germany) for the symptomatic treatment of productive cough associated with acute and chronic bronchopulmonary diseases. Its active ingredient is Ambroxol Hydrochloride, a substance characterized by its mucolytic properties. The medicine’s primary function is to restore the physiological clearance mechanisms of the respiratory tract by making thick, sticky bronchial secretions easier to remove.

Composition and Pharmacological Profile

Ambroxol is classified as a secretolytic and expectorant agent and is a synthetic derivative, chemically related to the natural substance vasicine. This classification indicates that the drug acts directly on mucus to change its physical properties. As a mucoactive drug and expectorant, its main action is to stimulate the production of thinner mucus and promote mucociliary activity.

General Therapeutic Purpose

The overarching therapeutic goal of Flavamed is to normalize viscous respiratory secretions and facilitate their expectoration. It is indicated for general use in typical scenarios where the patient experiences a wet, heavy cough due to conditions like acute bronchitis or tracheobronchitis. This function provides symptomatic relief by aiding the body in naturally clearing the airways and reducing the effort required for effective coughing.

What side effects are possible with Флавамед?

Possible Side Effects and Safety Information

This section summarizes the officially documented adverse reactions and safety restrictions for Флавамед, based strictly on government regulatory documents.

Adverse Reactions by Frequency

Side effects are categorized by frequency, reflecting how often they have been observed in clinical trials or post-marketing surveillance:

Frequency	System-Organ Class	Adverse Reaction
Common	Nervous system disorders	Dysgeusia (altered sense of taste)
Uncommon	Gastrointestinal disorders	Nausea, vomiting, diarrhea, abdominal pain, dyspepsia
Rare	Immune system disorders; Skin	Hypersensitivity reactions, rash, urticaria

Serious and Clinically Significant Reactions

The most clinically significant adverse reactions, which are rare or have an unknown frequency, are severe hypersensitivity reactions and skin disorders. Regulatory labeling highlights the potential for:

Anaphylactic Reactions: Including anaphylactic shock and angioedema, which are immediate, severe allergic responses.
Severe Cutaneous Adverse Reactions (SCARs): These include Erythema multiforme, Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Acute Generalised Exanthematous Pustulosis (AGEP). The frequency of these events is generally documented as 'Not Known' due to reliance on post-marketing reports, but their severity mandates explicit inclusion in the safety profile.

Safety-Related Restrictions

Regulatory documents include specific limitations and contraindications:

Age Restriction: The 30 mg strength of this medicine is specifically contraindicated (should not be used) in children under 6 years of age. This restriction is based on the regulatory assessment of the active substance content for this age group.
Hypersensitivity: The medicine is contraindicated in individuals with known hypersensitivity to the active substance (ambroxol) or any of the excipients.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Флавамед (Ambroxol Hydrochloride) overdose is documented based on the following safety domains.

Domain	Official Regulatory Statements
Documented Overdose Presentations	Symptoms are generally extensions of known undesirable effects, primarily including short-term restlessness and diarrhea. Other manifestations may include nausea, vomiting, epigastric pain, and excessive saliva secretion (sialorrhea).
Physiological Systems Affected	Gastrointestinal and Nervous System. Acute systemic effects like Hypotension are anticipated in cases of extreme overdosage based on preclinical data.
Population-specific Overdose Notes	Expected accumulation of Ambroxol metabolites is noted in patients with severe renal impairment.
Emergency-Response Statements	No specific antidote is known; therefore, treatment is defined as symptomatic and supportive therapy. Acute measures such as gastric lavage are generally not indicated, but may be considered only in cases of extreme overdosage within the initial two hours.
When Immediate Medical Help is Required	Consult a doctor or seek emergency medical treatment if the recommended dosage is exceeded. The medication must be immediately discontinued and a physician consulted if signs of a progressive skin rash (e.g., associated with blistering or mucosal lesions) or anaphylactic reactions are observed.

Connection to the Overall Overdose Profile

Regulatory documents define the overdose scenario by emphasizing the drug’s low acute toxicity profile while simultaneously mandating that any intake exceeding the recommended dose requires immediate medical consultation. Management is strictly supportive due to the absence of a specific antidote. This profile stresses the critical, non-dose-dependent need to seek urgent medical attention and discontinue the product if severe allergic manifestations develop.

Therapeutic Uses of Флавамед

Medicines containing ambroxol are generally used as expectorants to help make the mucus thinner and therefore easier to be cleared away in patients with short- or long-term diseases of the lungs or airways. It is used in therapeutic areas focused on easing secretions, relevant for managing symptoms across conditions such as acute and chronic bronchitis, bronchiectasis, and other respiratory disorders marked by viscid secretions.

The medication is applied in clinical settings that involve symptoms related to physical discomfort, where the primary problem is the production of thick, sticky mucus that interferes with daily functioning. It provides support that helps ease the overall symptom burden by supporting the clearance of tenacious phlegm, and may assist with easing the feeling of respiratory congestion.

Flavamed is commonly used across conditions characterized by periods of heightened symptoms, such as acute episodes or exacerbations of chronic conditions, that manifest with an ineffective, productive cough. It plays a role in managing symptoms that create noticeable physiological strain by contributing to improved mucus clearance, which supports the patient during difficult episodes by easing distress.

Quick Fact: Supportive Management for Viscid Mucus and Ineffective Cough The medication is considered relevant when supportive symptom management is appropriate for adults and children experiencing difficulty with clearing thick, tenacious secretions.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Флавамед — Official Regulatory Information

Category	Official Regulatory Classification
Populations for whom use is allowed	Adults and adolescents over 12 years are the standard labeled population. Use is established for children aged 2 to 12 years with specific liquid formulations
Populations for whom use is contraindicated	Patients with known hypersensitivity to ambroxol or any of the product’s excipients [1.1, 2.3]. Use is contraindicated for specific hereditary disorders, such as fructose or galactose intolerance, depending on the formulation [2.3, 2.6].
Age-related eligibility rules	The medicine is not recommended for children below 2 years of age for its primary use [2.3]. Older adults generally require no dose adjustment [2.6].
Condition-specific eligibility rules	Caution is mandatory in patients with severe renal impairment or severe hepatic disease [2.3]. Use is also restricted with caution in patients with gastric ulceration or a history of peptic ulcer disease [2.3].
Pregnancy and lactation status	Use is not recommended during the first trimester of pregnancy [1.1, 2.3]. The medicine is not recommended for use in nursing mothers as the substance is excreted in breast milk [1.1, 2.3].

Official Eligibility Statements:

Contraindicated for use in patients with known hypersensitivity to the active substance or excipients [1.1, 2.3].
The product is not recommended for children under 2 years for its mucolytic indication [2.3].
Use is not recommended during the first trimester of pregnancy or for nursing mothers [2.3].

Connection to the overall eligibility profile: The regulatory documents strictly define who can and cannot use the medicine by classifying populations based on absolute prohibitions (Contraindications) and conditional restrictions (Caution or Not Recommended). These constraints ensure that eligibility is dependent on age, the absence of specific allergies, and the functional status of the patient's liver and kidneys, preventing use in groups where the safety profile is not fully established or where risk is elevated [2.3].

What should I know about interactions with other medicines?

The official regulatory profile for Flavamed (Ambroxol Hydrochloride) outlines specific interaction patterns, primarily focusing on pharmacodynamic and pharmacokinetic considerations as documented in government labeling.

Drug-Drug Interaction Restrictions

Co-administration with cough suppressants (antitussive agents) is not recommended according to regulatory documents. This restriction is classified as a pharmacodynamic interaction, where the suppression of the cough reflex, combined with the drug's mucus-liquefying action, can result in excessive sputum accumulation and the risk of airway obstruction. Substances such as Codeine are cited as examples of medicines that should not be combined.

Exposure Modification

A specific finding documented in regulatory information is the interaction with certain antibiotics. Co-administration with medicines such as Amoxicillin, Cefuroxime, Erythromycin, and Doxycycline results in an officially observed increase of antibiotic concentrations in bronchopulmonary secretions and lung tissues.

Pharmacokinetic Considerations

Interaction classifications also account for population-specific factors. In patients with severe renal impairment or serious hepatic impairment, a pharmacokinetic alteration is expected. The regulatory label notes that accumulation of Ambroxol metabolites should be anticipated in cases of severe renal insufficiency due to reduced clearance. No mandatory timing or separation rules are documented for other substances, and no clinically unfavorable interactions concerning major metabolic enzymes (CYP) are consistently reported in primary regulatory texts.

Mechanism of Action

The mechanism of action for Phi лавамед (Ambroxol) is defined by three distinct peripheral physiological actions that target the properties of bronchial secretions and sensory input from the airways.

Modulation of Mucus Viscoelasticity

This primary mechanism involves the drug acting on Type II pneumocytes in the lungs to stimulate the synthesis and release of pulmonary surfactant. Surfactant embeds itself in the thick mucus, reducing its adhesion and surface tension, which in turn lowers the viscoelasticity of the phlegm. This change in rheology is the essential molecular step that modifies the kinetics of the mucociliary clearance pathway.

Enhancement of Airway Fluid Secretion

Ambroxol also exerts a secretomotoric effect by promoting the activity of submucosal glandular serous cells. This stimulation increases the volume of thin, aqueous fluid secreted into the airways. The added fluid acts to dilute the accumulated, viscous mucus, supporting the work of the surfactant and influencing the flow dynamics, which affects the ability of the cilia to propel secretions.

Local Blockade of Sensory Signaling

A separate mechanism involves the drug acting as a local anesthetic by binding to and blocking neuronal voltage-gated Na^+ channels in the sensory nerve endings of the pharynx and upper airways. This action stabilizes the nerve membrane and inhibits the conduction of afferent (irritative) signals. This results in a physiological consequence involving the inhibition of localized sensory signaling.

Dosage and Administration Information

Administration Protocol and Official Dosing

The administration of Флавамед, which contains the active ingredient ambroxol hydrochloride, is for oral use via forms such as tablets or solutions. Standard usage involves a two-tiered dosing schedule for short-term symptomatic treatment.

Administration Parameter	Official Instructions for Adults
Initial Dosing	30 mg, three times daily, for the first 2 to 3 days (90 mg daily total).
Maintenance Dosing	30 mg, twice daily (60 mg daily total).
Maximum Dose	Should not exceed 120 mg per day.

The medication is administered after meals and should be taken with an appropriate amount of fluid. Liquid forms must be measured using the provided dosing device to ensure accurate intake.

Treatment is generally intended for a short duration, and use is not to be extended beyond 4 to 5 days without professional medical guidance. Dosage adjustments are utilized for specific patient populations. For individuals with severe renal or hepatic impairment, the dose is typically reduced or the interval between administrations is extended. If a dose is forgotten, the instruction is to skip the missed dose and resume the next scheduled administration, as double doses are prohibited.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Флавамед (Ambroxol)

The research landscape for Флавамед, whose active ingredient is Ambroxol, was studied in contexts where symptoms included thick respiratory secretions and difficulty with coughing and breathing. The available evidence, evaluated by regulatory bodies and scientific literature, helps contextualize what has been observed in clinical settings and what questions remain unanswered.

Evidence for Mucolytic Use in Acute and Chronic Respiratory Diseases

Ambroxol was studied for use in conditions characterized by fluctuating or episodic manifestations such as acute bronchitis and flare-ups of chronic conditions. The research included numerous short-term Randomized Controlled Trials (RCTs), where the medicine was evaluated in diverse groups of patients. The outcomes primarily measured were patient-reported outcomes describing perceived discomfort related to cough severity, mucus thickness, and the difficulty of expectoration (coughing up phlegm).

Findings describe patterns observed in the studies where measurements indicated patterns related to changes in the physical properties of respiratory secretions. Studies report how symptoms evolved in the observed populations during the study period. This body of evidence is associated with a High to Moderate evidence level for the short-term outcomes studied.

Research Structure for Adjunctive Use in Secretory Otitis Media

The use of Ambroxol in ear, nose, and throat (ENT) conditions, specifically for fluid accumulation in the middle ear (Secretory Otitis Media), was studied in contexts involving thick secretions in this area. Research examined this use primarily through the collection and analysis of multiple existing trials using Systematic Reviews and Meta-Analyses.

The pooled data describes patterns observed in the measurements of functional measures when the substance was evaluated in patients receiving it as an additional component to their main course of treatment. This evidence base is generally associated with a Moderate evidence level in scientific literature.

Research Gaps and Areas of Uncertainty

While research exploring short-term symptom changes has been conducted, long-term effects are not fully established across all respiratory uses. Follow-up durations were limited in many of the core acute studies, meaning that findings largely reflect the specific conditions under which they were conducted. Evidence quality varies across studies, and for the primary respiratory use, the variability in reported outcomes means that certainty remains low in some specific endpoints. The regulatory observation regarding insufficient efficacy evidence for specific pediatric age groups in certain contexts highlights a clear research limitation frame.

Key Studies & References WHO ATC Code R05CB06 (Ambroxol) - Expectorants, excl. combinations with cough suppressants

Frequently Asked Questions (FAQ)

Common questions about Флавамед (FAQ)

Q: What is the longest period of time people typically use Флавамед for?

A: Regulatory documents describe the intended duration of treatment as generally short-term for symptomatic relief. Official guidance states that use should typically not be extended beyond 4 to 5 days without first consulting a healthcare professional. This reflects the intended short-term nature of treatment for acute conditions.

Q: Can older people (70+) use Флавамед safely?

A: Official information indicates that age, including older age, does not affect the drug's actions to a clinically relevant extent. Therefore, dose adjustment is generally described as unnecessary for older adults based on regulatory assessment.

Q: Are there special warnings for women who might become pregnant while using Флавамед?

A: Official regulatory documents advise that this medicine is not recommended for use during the first trimester (the first three months) of pregnancy. Women who are pregnant, planning to become pregnant, or breastfeeding are advised to discuss use with a healthcare provider.

Q: Does taking Флавамед with food change how the body absorbs it?

A: Official product information suggests taking the medicine after meals, which may help minimize stomach discomfort, such as nausea or pain. The absorption profile of the drug may vary slightly between different formulations.

Q: Is Флавамед considered a painkiller or an anti-inflammatory medicine?

A: The medicine is primarily classified as a mucolytic agent, meaning it helps to clear mucus and phlegm. However, studies and official information have also documented that the active ingredient possesses a local anesthetic (pain-relieving) effect for acute sore throat, and it has been observed to have anti-inflammatory properties.

Q: Is Флавамед appropriate for use by teenagers (13-17)?

A: Official product information states that the medicine is typically intended for use by adults and adolescents who are over 12 years of age. Eligibility for use is dependent on the specific age and formulation of the medicine.

Q: Does Флавамед work on the brain or just on the local area of concern?

A: The primary way the medicine works is described in official documents as peripheral actions (local) within the airways, helping to clear mucus. However, central nervous system effects, such as drowsiness, have been noted in safety profiles, especially in cases of overdosage.

Q: Does Флавамед have a generic name that is easier to find?

A: The generic name for the active ingredient contained in Флавамед is Ambroxol or Ambroxol Hydrochloride.

Q: How quickly should I expect to feel a difference after starting Флавамед?

A: Official pharmacokinetic information indicates that the onset of action, which is when the medicine begins to work in the body, generally occurs about 30 minutes after the medication has been taken orally.

Q: Why do some people say Флавамед makes them feel a bit sleepy?

A: Official safety profiles list drowsiness (somnolence) and dizziness as potential effects of the medicine. This is a common adverse reaction that is reported.

Q: Can Флавамед affect my ability to drive or operate machinery?

A: Official safety information advises that because the medicine may cause drowsiness or dizziness, it could have a minor influence on the ability to drive or use machinery. Regulatory documents mention that caution may be necessary when performing activities that require full attention.

Q: Are there any common foods or drinks that should be avoided while using Флавамед?

A: Official regulatory documents indicate that co-administration with alcoholic beverages or fruit juices is not recommended. This is referenced in the patient information leaflet.

Q: Can Флавамед be used by people with a history of kidney problems?

A: Regulatory documents state that the medicine must be used with caution in patients who have severe renal (kidney) impairment. Dose reduction or extending the time between doses is frequently referenced in regulatory documents for these specific patient populations due to the risk of the drug's metabolites accumulating.

Q: Can Флавамед be used during the flu or a common cold?

A: The medicine is indicated for the symptomatic relief of productive cough associated with acute bronchopulmonary diseases. Since a productive cough is often a symptom of the flu or a common cold, the medicine may be used to help manage this specific symptom.

Q: Do official sources mention any risk for people with liver disease using Флавамед?

A: Official regulatory documents note that the medicine must be used with caution in patients with severe hepatic (liver) disease. Dose reduction is typically referenced in regulatory documents because the accumulation of the parent drug may be expected in cases of severe liver impairment.

Q: What is the general duration of action for a single dose of Флавамед?

A: The plasma half-life of ambroxol and its metabolites is documented in official pharmacokinetic data as approximately 22 hours.

Q: Are there any dietary restrictions mentioned in the patient information leaflet for Флавамед?

A: Official regulatory documents mention that it is not recommended to take the medication with alcoholic beverages or fruit juices.

Q: Can Флавамед be crushed or broken if the tablet is too large?

A: Official product information states that the tablets or caplets must be swallowed whole and not chewed, crushed, or broken. This constraint is in place because altering the form can affect how the medicine works or is absorbed.

How should Флавамед be stored and disposed of?

How to Store and Dispose of Флавамед

Official regulatory documents define strict requirements for storing and disposing of Флавамед (Ambroxol Hydrochloride) to ensure its stability.

Scope Element	Official Regulatory Requirement
Temperature Requirements	Store at a temperature not exceeding 30 C
Protection Requirements	Keep in the original, tightly closed container; protect from light and moisture
Child Safety	Keep out of the sight and reach of children
Disposal Instructions	Do not dispose of via wastewater or drains; follow local regulations for unused or expired medicines, such as drug take-back programs

The regulatory profile mandates storing Флавамед at room temperature, not exceeding 30 C, and requires protection from moisture and light by keeping it in its original, closed packaging. The label explicitly states the product must be kept out of the sight and reach of children. Disposal instructions require consulting local regulations for take-back programs and prohibit flushing the product into drains to protect the environment.

Флавамед